<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56924">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01782833</url>
  </required_header>
  <id_info>
    <org_study_id>021-KOA-1201n</org_study_id>
    <nct_id>NCT01782833</nct_id>
  </id_info>
  <brief_title>Pletaal SR Post Marketing Observational Study</brief_title>
  <acronym>PLT SR PMOS</acronym>
  <official_title>A Prospective, Post Marketing Observational Study to Evaluate the Safety of Pletaal® SR Capsule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this
      study is observational in nature to collect the safety data after administrating the Pletaal
      SR capsule, from baseline to 16 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in a prospective, single-arm, multi-center format. As this
      study is observational in nature, the patient's follow-up is not prescriptive in nature and
      must be left up to the judgment of the physician (investigator), within the period of
      observation set forth in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The incidence rate and the number of AE/ADRs</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of Tarchycardia and Palpitation after Pletaal® SR capsule administration</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and percentage of drop-out patients according to Aes</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between AE and drug compliance according to patient's character</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Treatment of Ischemic Symptom and Prevention of Recurrence of Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Pletaal</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pletaal</intervention_name>
    <arm_group_label>Pletaal</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient who has below indication (1. Treatment of ischemic symptoms including
        ulceration, pain and coldness in chronic arterial occlusion (Berger's disease,
        arteriosclerosis obliterans, diabetic peripheral angiopathy). 2. Prevention of recurrence
        of cerebral infarction (excluding cardiogenic cerebral embolism).)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients must meet all of the following inclusion criteria to be eligible for enrollment
        into the study :                   1. Patients who are prescribed Pletaal® SR capsule
        treatment as per investigator's medical judgment for adults aged 19 and over.

        2. Patients who gave written authorization to use their personal and health data
                                             Physician (Investigator) will refer to the product
        market authorization (package insert) for inclusion criteria.

        Exclusion Criteria:

          -  Patients presenting with any of the following will not be included in the study
                                                                 1. Patients with hemorrhage 2.
             Patients with congestive heart failure 3. Patients with known hypersensitivity to
             Cilostazole or any ingredients of Pletaal® 4. Women who are pregnant or may possibly
             become pregnant 5. Patients who is not eligible to participate this study as
             investigator's medical judgment                                         Physician
             (Investigator) will refer to the product market authorization (package insert) for
             exclusion criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ji Yoon Jung</last_name>
    </contact>
    <investigator>
      <last_name>Ji Yoon Jung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHIC Ilsan Hospital</name>
      <address>
        <city>Kyunggido Goyangsi</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Hong Lee</last_name>
    </contact>
    <investigator>
      <last_name>Jun Hong Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Pail Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Myeon Jung</last_name>
    </contact>
    <investigator>
      <last_name>Jae Myeon Jung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Man Ho Kim</last_name>
    </contact>
    <investigator>
      <last_name>Man Ho Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 31, 2013</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
